title: GPR55 and the vascular receptors for cannabinoids.
abstract: CB1 and CB2 receptors mediate most responses to cannabinoids but not some of the cardiovascular actions of endocannabinoids such as anandamide and virodhamine, or those of some synthetic agents, like abnormal cannabidiol (abn-cbd). These agents induce vasorelaxation which is antagonised by rimonabant but only at high concentrations relative to those required to block CB1 receptors. Vasorelaxation to anandamide is sensitive to Pertussis toxin (though that to abn-cbd is not), and so is thought to be mediated by a G protein-coupled receptor through Gi/o. An orphan receptor, GPR55, apparently a cannabinoid receptor, is activated by abn-cbd, but is not the receptor mediating vasorelaxation to this agent, as the response persists in vessels from GPR55 knockout mice. However, the activity of anandamide in GPR55 knockout mice is not yet reported and so the role of GPR55 as a cannabinoid receptor mediating vascular responses has yet to be finalised.
authors: Department of Pharmacology, University of Cambridge, Cambridge, UK. crh1@cam.ac.uk
authors: C R
authors: CR
authors: Hiley
authors: S S
authors: SS
authors: Kaup
mesh_terms: D000818:Animals; D002186:Cannabinoids / Q000494:pharmacology*; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists; D043882:Receptors, Cannabinoid; D043562:Receptors, G-Protein-Coupled / Q000819:agonists* / Q000378:metabolism; D014664:Vasodilation / Q000187:drug effects
chemical_list: D002186:Cannabinoids; C524885:GPR55 protein, human; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D043882:Receptors, Cannabinoid; D043562:Receptors, G-Protein-Coupled
references: Mol Pharmacol. 2003 Mar;63(3):699-705
references: 12606780
references: Pharmacol Rev. 2002 Jun;54(2):161-202
references: 12037135
references: Br J Pharmacol. 2004 Jun;142(3):435-42
references: 15148250
references: Br J Pharmacol. 1997 Dec;122(8):1573-84
references: 9422801
references: Br J Pharmacol. 1998 Oct;125(3):533-41
references: 9806337
references: Hypertension. 1999 Jan;33(1 Pt 2):429-34
references: 9931142
references: Brain Res Mol Brain Res. 1999 Feb 5;64(2):193-8
references: 9931487
references: Eur J Pharmacol. 2005 Jan 10;507(1-3):211-21
references: 15659311
references: Br J Pharmacol. 2005 Jun;145(4):514-26
references: 15821751
references: Trends Pharmacol Sci. 2006 Jan;27(1):1-4
references: 16318877
references: Chem Biol Drug Des. 2006 Mar;67(3):252-3
references: 16611220
references: Br J Pharmacol. 2007 Nov;152(5):825-31
references: 17704827
references: Br J Pharmacol. 2003 Apr;138(7):1320-32
references: 12711633
references: Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14136-41
references: 10570211
references: Br J Pharmacol. 2002 Mar;135(5):1191-8
references: 11877326
references: Am J Physiol Heart Circ Physiol. 2002 Jun;282(6):H2046-54
references: 12003810